DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue... Show more
The Moving Average Convergence Divergence (MACD) for DSRLF turned positive on June 02, 2025. Looking at past instances where DSRLF's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
DSRLF moved above its 50-day moving average on June 12, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DSRLF crossed bullishly above the 50-day moving average on June 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for DSRLF moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DSRLF as a result. In of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for DSRLF entered a downward trend on June 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.101) is normal, around the industry mean (24.463). P/E Ratio (27.322) is within average values for comparable stocks, (77.706). DSRLF's Projected Growth (PEG Ratio) (179.924) is very high in comparison to the industry average of (5.667). Dividend Yield (0.012) settles around the average of (0.018) among similar stocks. P/S Ratio (3.702) is also within normal values, averaging (43.062).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DSRLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DSRLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FELC | 34.30 | 0.20 | +0.59% |
Fidelity Enhanced Large Cap Core ETF | |||
FTXG | 22.04 | 0.05 | +0.23% |
First Trust Nasdaq Food & Beverage ETF | |||
THNR | 22.70 | 0.04 | +0.18% |
Amplify Weight Loss Drug & Treatment ETF | |||
AVXC | 56.35 | -0.03 | -0.06% |
Avantis Emerging Markets Ex-Chn Eq ETF | |||
PALL | 103.53 | -0.38 | -0.37% |
abrdn Physical Palladium Shares ETF |
A.I.dvisor tells us that DSRLF and TWST have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DSRLF and TWST's prices will move in lockstep.
Ticker / NAME | Correlation To DSRLF | 1D Price Change % | ||
---|---|---|---|---|
DSRLF | 100% | N/A | ||
TWST - DSRLF | 28% Poorly correlated | -2.73% | ||
LMAT - DSRLF | 26% Poorly correlated | +0.21% | ||
LUNG - DSRLF | 21% Poorly correlated | +0.39% | ||
AVCRF - DSRLF | 20% Poorly correlated | +111.76% | ||
CNVVY - DSRLF | 16% Poorly correlated | -2.18% | ||
More |